NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on identifying growth opportunities for corporate and institutional clients, today announced the expansion of its Healthcare Research Team with the addition of Senior Research Analyst Yale Jen, Ph.D.
Dr. Jen joins ROTH from Maxim Group where he was a senior equity research analyst focusing on the biotechnology sector since 2007. Prior to Maxim Group, he held associate analyst positions with Rodman & Renshaw and Thomas Weisel Partners. His investment views have been cited in The Wall Street Journal, Bloomberg, Thomson Reuters and Dow Jones Newswires. Prior to joining Wall Street, Yale spent several years with KPMG Corporate Finance Life Sciences Group and Genesis Group Associates focusing on mergers and acquisitions and pipeline optimization for pharmaceutical and biotechnology clients. Dr. Jen holds a Ph.D. in molecular biology from Cornell Medical School and an MBA from Rutgers University.
“Yale’s exceptional background in life sciences research represents an outstanding asset for ROTH as we continue to expand our healthcare practice and broaden our research coverage universe,” said Byron Roth, CEO. “We have a strong track record of helping fast-growing companies raise the capital required to complete the development of their product portfolio or fund the commercial launch of their programs. We also work closely with management and boards in evaluating merger and acquisition opportunities, licensing transactions and strategic partnerships to accelerate growth and enhance shareholder value. Yale brings a solid network of relationships in the biotechnology sector which will be a great resource to our team.”
Dr. Jen commented, “Joining ROTH is an exciting professional opportunity and I’m looking forward to working with the firm’s respected healthcare research team. The strength and prominence of ROTH’s healthcare franchise in the investment community is highly regarded as a valuable platform from which to provide sponsorship to emerging companies in this sector.”
Since the beginning of 2010, ROTH has assisted Healthcare clients in raising approximately $1.9 billion in over 90 transactions. ROTH’s Healthcare clients cover a broad spectrum of sectors including biotechnology, pharmaceuticals, medical technologies and devices and healthcare services.
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH) is a relationship-driven investment bank focused on identifying growth opportunities for corporate and institutional clients. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading and market-making services. Headquartered in Newport Beach, CA, ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S., Hong Kong and a Shanghai Representative Office. For more information on ROTH, please visit www.roth.com.
For information about the upcoming ROTH Capital Partners 24th Annual Growth Stock Conference to be held March 11–14, 2012, at The Ritz Carlton, Dana Point, California, please visit: http://www.roth.com/main/Page.aspx?PageID=7250.